Genomics and Biotech ETFs
Gene editing and DNA sequencing make a thrilling story, but biotech is a graveyard of failed trials. Here's how genomics ETFs are built and why they swing so hard.
Don't have time? Here's what you need to know:
- 1Broad biotech funds are anchored by profitable drugmakers; genomics funds concentrate on speculative, often pre-revenue gene-editing firms.
- 2ARKG fell roughly 70-80% from its 2021 peak — a reminder that transformative tech and good returns at a given price are not the same thing.
- 3Genomics funds typically charge ~0.50-0.75%, a guaranteed cost on top of a highly uncertain payoff.
- 4For lower-volatility healthcare exposure, a broad sector fund like VHT spreads across pharma, devices, and insurers.
Genomics Is Not the Same as Broad Biotech
It is easy to lump these together, but genomics and biotech funds behave quite differently. A broad biotech ETF holds the large, profitable drug developers — names like Amgen, Gilead, Vertex, and Regeneron — alongside a tail of smaller firms. These funds are volatile, but anchored by companies with real revenue and approved products.
A genomics fund is far more speculative. It concentrates on gene editing (CRISPR Therapeutics, Intellia, Beam), DNA sequencing hardware, and early-stage cell and gene therapy companies, many of which are pre-revenue and years from a marketable product. ARKG, the best-known genomics fund, became the archetype: it soared during the 2020-2021 innovation boom and then fell roughly 70-80% from its peak as unprofitable growth stocks were repriced by rising rates.
The lesson is to read the holdings before you buy. 'Biotech' and 'genomics' on the label can mean wildly different risk profiles, from established cash-generating pharma to a basket of clinical-stage moonshots.
Why Biotech Swings So Violently
Individual biotech stocks are close to binary. A single Phase 3 trial readout or FDA decision can send a clinical-stage company up 100% or down 80% in a day, because the entire value of the firm hinges on whether one drug works and gets approved. Most experimental drugs fail somewhere in the pipeline.
An ETF cushions this by spreading across dozens of companies, so no single trial failure is fatal to your position. That diversification is the main reason to use a fund rather than pick stocks here. But it does not remove the sector-level risk: biotech is highly sensitive to interest rates (because profits are far in the future), to drug-pricing politics, and to the broad risk appetite for speculative growth. When that appetite turns, the whole group falls together.
Important: Diversification across a basket protects you from one failed trial, not from a sector-wide repricing. Genomics funds can still drop 50%+ in a risk-off year.
The Funds and Their Fees
The genomics and biotech space spans a range from cheap and broad to expensive and narrow. Broad, index-based biotech funds are relatively inexpensive. Actively managed, narrowly thematic genomics funds charge considerably more — often around 0.50% to 0.75% — because they are betting on selection and a specific innovation story.
Cost matters more here than it might seem, because expected returns from speculative themes are so uncertain. Paying an extra half a percent a year is a guaranteed cost layered on top of a deeply unguaranteed payoff.
| Fund type | Example focus | Typical expense ratio | Risk character |
|---|---|---|---|
| Broad biotech (index) | Large + small biotech | ~0.40-0.50% | Volatile, revenue-anchored |
| Genomics (thematic) | Gene editing, sequencing | ~0.50-0.75% | Highly speculative, pre-revenue |
| Healthcare sector | Pharma, devices, insurers | ~0.10% | Defensive, diversified |
Tip: If you want healthcare exposure without the rollercoaster, a broad sector fund like VHT gives you pharma, devices, and insurers with a fraction of the volatility.
Where Genomics Fits in a Portfolio
Genomics is a satellite holding for investors who can tolerate large drawdowns and a long, uncertain time horizon. The underlying science — gene editing, personalized medicine, cheaper sequencing — is genuinely transformative, but 'transformative technology' and 'good investment at this price' are separate questions. The 2021 cohort learned that distinction painfully.
If you want healthcare in your portfolio without binary trial risk, a broad sector fund like VHT spreads across pharma, medical devices, insurers, and services, and behaves far more defensively. Reserve genomics funds for a small, deliberate slice — money you can leave untouched for a decade and would not miss if a few of the bets never pan out. A broader healthcare sector fund is the more durable core.
Frequently Asked Questions
What's the difference between a biotech ETF and a genomics ETF?
A broad biotech ETF is anchored by large, profitable drugmakers like Amgen and Vertex, so it is volatile but grounded in real revenue. A genomics ETF concentrates on speculative, often pre-revenue gene-editing and sequencing companies, which makes it far more volatile and prone to large drawdowns, as ARKG's roughly 70-80% fall from its 2021 peak showed.
Why is biotech so volatile?
Individual biotech firms are close to binary bets — a single trial result or FDA decision can swing a stock 80% in a day, and most experimental drugs fail. The sector is also very sensitive to interest rates and risk appetite because so much of its value lies in distant future profits. An ETF spreads across many companies to soften single-stock risk, but not sector-wide swings.
Are genomics ETFs worth the risk?
Only as a small satellite for investors with a long horizon and a strong stomach for drawdowns. The underlying science is real, but the funds are expensive (often 0.50-0.75%) and deeply speculative, and a compelling technology story does not guarantee good returns at today's prices. For most people, a broad healthcare fund like VHT is the more sensible exposure.
Is a healthcare sector ETF a safer alternative?
Yes, considerably. A broad healthcare fund such as VHT holds large pharmaceutical firms, device makers, and insurers, which gives it defensive characteristics and far lower volatility than a genomics fund. You give up the lottery-ticket upside of early-stage gene editing in exchange for a steadier, diversified exposure to the sector.
Further Reading
Free Tools
Alex Harrington
CFA Level II Candidate, Finance & Economics
Alex Harrington is an independent ETF researcher and personal finance writer with over 8 years of experience analyzing exchange-traded funds. A CFA Level II candidate with a background in economics, Alex has reviewed 800+ ETFs and helped thousands of beginners build their first investment portfolios through clear, jargon-free education.
This content is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Consult a licensed financial advisor before making investment decisions.